J. Tyler Martin named president of Dynavax Technologies

J. Tyler Martin has been promoted by Dynavax Technologies to the newly-created position of president.

Martin, who joined Dynavax as chief medical officer in February 2009, was also appointed to the company's board of directors.

"Tyler has made many significant contributions to advancing the company's programs since joining us a little more than a year ago, including leading the successful effort to remove the clinical hold on HEPLISAV, reinitiating clinical development and moving our novel Universal Flu vaccine product candidate into the clinic," Dino Dina, Dynavax's CEO, said. "We look forward to his continuing achievements in his new role."

Martin has 20 years of biotechnology industry experience. Before joining Dynavax, he was president of Humabs LLC and vice president of development at Chiron.

While at Chiron, Martin led a team that was responsible for developing the novel vaccine adjuvant MF59, which was the first vaccine adjuvant licensed by regulatory agencies since alum, and approved as FLUAD influenza vaccine in Europe.

Martin has also held senior development and research positions at Sangamo Inc., Valentis Inc., and SyStemix/GTI.

Martin holds a B.S. in chemistry and an M.D. from the University of Nebraska. He completed his fellowship in pediatric infectious diseases and molecular microbiology at Washington University in St. Louis.